-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 14, 2022, Bavarian Nordic announced that the U.
RSV is a very common infectious agent, divided into two subtypes according to antigenicity: type A and type
MVA-BN RSV is a vaccine candidate developed by Bavarian Nordic to prevent RSV and is currently targeting elderly individuals
picture
Image source: 123RF
Last year the company announced results from a double-blind, placebo-controlled Phase 2 clinical trial
In addition, another phase 2 clinical trial in 421 elderly subjects aged 55 years and older demonstrated that the vaccine was well tolerated, induced broad and durable anti-RSV antibody and T cell responses, and may be effective in preventing RSV is an important mucosal immune response
References:
[1] Bavarian Nordic Announces Breakthrough Therapy Designation For Its Rsv Vaccine Candidate For The Prevention Of Respiratory Syncytial Virus In Older Adults.
(Original abridged)